U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07559500) titled 'Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)' on April 29.
Brief Summary: Background:
Glucagon-like peptide 1 (GLP-1) agonist drugs are used to treat diabetes and aid weight loss. They may also help reduce cravings for drugs and alcohol. Researchers want to know if a GLP-1 drug (tirzepatide) can lessen the urge to drink in people with alcohol use disorder (AUD).
Objective:
To learn how the brains of people with AUD respond to a GLP-1 drug.
Eligibility:
People aged 21 to 65 years with AUD who are non-treatment seeking. They must be enrolled in protocol 14-AA-0181. Healthy volunteers are also needed.
Design:
...